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Introduction: Familial hypercholesterolaemia (FH) is a known major cause of premature heart disease. The risks 
of atherosclerotic disease in other vascular regions are less known. We determined the risk of major cardiovascular 
disease (CVD) outcomes associated with clinical FH. 
Methods: In a retrospective cohort study (1 January 1999 to 22 July 2016), we randomly-matched 14,097 UK 
subjects with clinical FH diagnoses or characteristics (Simon-Broome definite (SB) or Dutch Lipid Clinic 
Network (DLCN) Score >8) to 42,506 subjects without FH by age, sex, general practice. We excluded those with 
CVD at baseline. Incident rates of coronary heart disease (CHD), stroke or transient ischaemic attack (TIA) and 
peripheral vascular disease (PVD) were estimated over a median 13.8 years follow-up. Cox proportional hazards 
regression models stratified on matched-pairs, determined adjusted hazards ratios (HR) for incident CVD in FH 
compared to non-FH subjects. 
Results: The incidence rates (95% CI) of CVD in FH and non-FH subjects (per 1000 person-years at risk) were 
25.6 (95% CI 24.8-26.3) and 2.9 (95% CI 2.8-3.1) respectively. The risk of CHD, stroke/TIA and PVD were 
higher in FH compared to non-FH subjects: CHD (HR 10.63, 95% CI 9.82-11.49), stroke/TIA (HR 6.74, 95% CI 
5.84-7.77), PVD (HR 7.17, 95% CI 6.08-8.46). At baseline, 19% of the patients with FH were on lipid- lowering 
treatment with only 3.2% on high-intensity statins. Over the duration of follow-up, 75% of these subjects with FH 
had been commenced on lipid-lowering treatment with 38% on high intensity statins. A higher proportion of 
subjects with FH diagnosis were on lipid-lowering treatment compared to undiagnosed subjects with FH 
characteristics (SB/DLC phenotype for definite FH). Diagnosed FH subjects had a two-fold higher risk of CHD 
than subjects without FH. Subjects with undiagnosed FH but the clinical phenotype, had a 15-fold higher risk of 
CHD as well as statistically higher risk of stroke/TIA and PVD 
Conclusions: In addition to the recognised increased risk of CHD, subjects with FH have greatly elevated risk of 
stroke/TIA and PVD. The risk of stroke/TIA and PVD is particularly higher in undiagnosed subjects with the FH 
phenotype. This emphasises the importance of early diagnosis and preventive interventions to reduce overall CVD 
risk in these individuals. 
 
